Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners.Invivoscribe Marketing2021-02-26T19:10:05-08:00May 12th, 2020|2020 Press Releases, Press Releases| Read more
Invivoscribe® Releases LeukoStrat® CDx FLT3 Mutation Assay as CE-marked IVD Assay Kit.wmm2021-02-26T19:12:46-08:00August 1st, 2017|2017 Press Releases, Press Releases| Read more